Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)

2014 ◽  
Vol 50 (18) ◽  
pp. 3116-3124 ◽  
Author(s):  
Isabelle Trouilloud ◽  
Anne-Claire Dupont-Gossard ◽  
David Malka ◽  
Pascal Artru ◽  
Mélanie Gauthier ◽  
...  
Keyword(s):  
Dose Rate ◽  
Pancreatic Adenocarcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Fixed Dose ◽  
Line Treatment ◽  
First Line ◽  
Metastatic Pancreatic Adenocarcinoma ◽  
Fixed Dose Rate ◽  
First Line Treatment

Phase II study of erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e14565-e14565 ◽  
Author(s):  
M. Milella ◽  
V. Vaccaro ◽  
I. Sperduti ◽  
E. Bria ◽  
A. Gelibter ◽  
...  
Keyword(s):  
Dose Rate ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Fixed Dose ◽  
Line Treatment ◽  
First Line ◽  
Fixed Dose Rate ◽  
Adenocarcinoma Of The Pancreas ◽  
First Line Treatment

Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma ( GATE 1)

2020 ◽  
Vol 148 (3) ◽  
pp. 682-691
Author(s):  
Eric Assenat ◽  
Laurent Mineur ◽  
Caroline Mollevi ◽  
Evelyne Lopez‐Crapez ◽  
Catherine Lombard‐Bohas ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
Metastatic Pancreatic Adenocarcinoma ◽  
First Line Treatment

A phase II study of fixed-dose rate (FDR) gemcitabine plus cisplatin for metastatic pancreatic adenocarcinoma (PanCa)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4107-4107
Author(s):  
A. H. Ko ◽  
E. Dito ◽  
B. Schillinger ◽  
A. P. Venook ◽  
E. K. Bergsland ◽  
...  
Keyword(s):  
Dose Rate ◽  
Pancreatic Adenocarcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Fixed Dose ◽  
Metastatic Pancreatic Adenocarcinoma ◽  
Fixed Dose Rate

A phase II study of fixed-dose rate (FDR) gemcitabine plus cisplatin for metastatic pancreatic adenocarcinoma (PanCa)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4107-4107
Author(s):  
A. H. Ko ◽  
E. Dito ◽  
B. Schillinger ◽  
A. P. Venook ◽  
E. K. Bergsland ◽  
...  
Keyword(s):  
Dose Rate ◽  
Pancreatic Adenocarcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Fixed Dose ◽  
Metastatic Pancreatic Adenocarcinoma ◽  
Fixed Dose Rate

First-line treatment of inoperable pancreatic adenocarcinoma with lipid complexed paclitaxel nanoparticles plus gemcitabine compared with gemcitabine monotherapy. A prospective RCT - phase II study

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 4618-4618 ◽  
Author(s):  
M. Löhr ◽  
S. Haas ◽  
W. Bechstein ◽  
M. Karrasch ◽  
A. Mescheder ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree: series of 106 consecutive patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14099-14099
Author(s):  
P. Malaguti ◽  
M. Milella ◽  
A. J. Gelibter ◽  
G. Bossone ◽  
I. Sperduti ◽  
...  
Keyword(s):  
Dose Rate ◽  
Clinical Benefit ◽  
Therapeutic Index ◽  
Serum Levels ◽  
Fixed Dose ◽  
Line Treatment ◽  
First Line ◽  
Fixed Dose Rate ◽  
Clinical Benefit Response ◽  
First Line Treatment

14099 Background: Our group recently published a phase II trial of GEM infused at fixed dose-rate of 10 mg/m2/min over 100 min in patients with advanced PDAC and BTC. (Cancer September 15,2005). Given the promising results obtained in the first 40 pts, we expanded the cohort under an observational protocol and this is the report of such experience. Methods: From April 2002 to September 2005, 106 advanced PDAC (n = 75) or BTC (n = 31) pts (median age: 63 yrs, range 28–82; M/F: 48/58; PDAC/BTC: 75/31; LA/Met: 36/70; PS 0/1/2/3: 31/53/17/5) were treated with GEM 1000 mg/m2 at the fixed dose-rate of 10 mg/m2/min for 7 consecutive wks and weekly × 3 q4 wks thereafter (FDR-GEM). All patients and 1154 treatment weeks were evaluable for toxicity, 100 were evaluable for response, 87 patients were evaluable for clinical benefit response (CBR) according to Burris criteria, and 56 patients had elevated CA19.9 serum levels at entry. Results: From April 2002 to September 2005, 106 advanced PDAC (n = 75) or BTC (n = 31) pts (median age: 63 yrs, range 28–82; M/F: 48/58; PDAC/BTC: 75/31; LA/Met: 36/70; PS 0/1/2/3: 31/53/17/5) were treated with GEM 1000 mg/m2 at the fixed dose-rate of 10 mg/m2/min for 7 consecutive wks and weekly × 3 q4 wks thereafter (FDR-GEM). All patients and 1154 treatment weeks were evaluable for toxicity, 100 were evaluable for response, 87 patients were evaluable for clinical benefit response (CBR) according to Burris criteria, and 56 patients had elevated CA19.9 serum levels at entry. Conclusions: The results obtained with FDR-GEM in a series of 106 consecutive pts confirm previous results obtained in smaller series and suggest that pharmacokinetically rationale GEM scheduling may improve its therapeutic index. FDR-Gem may constitute a viable alternative to standard Gem infusion as first-line treatment in advanced PDAC and BTC. No significant financial relationships to disclose.

scholarly journals Fixed‐Dose‐Rate Gemcitabine: A Viable First‐Line Treatment Option for Advanced Pancreatic and Biliary Tract Cancer

2010 ◽  
Vol 15 (2) ◽  
Author(s):  
Michele Milella ◽  
Alain J. Gelibter ◽  
Maria Simona Pino ◽  
Giandominik Bossone ◽  
Paolo Marolla ◽  
...  
Keyword(s):  
Dose Rate ◽  
Biliary Tract ◽  
Treatment Option ◽  
Biliary Tract Cancer ◽  
Fixed Dose ◽  
Line Treatment ◽  
First Line ◽  
Tract Cancer ◽  
Fixed Dose Rate ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document